MET-Activating Ubiquitin Multimers

Angew Chem Int Ed Engl. 2023 Sep 4;62(36):e202307157. doi: 10.1002/anie.202307157. Epub 2023 Jul 31.

Abstract

Receptor tyrosine kinases (RTKs) are generally activated through their dimerization and/or oligomerization induced by their cognate ligands, and one such RTK hepatocyte growth factor (HGF) receptor, known as MET, plays an important role in tissue regeneration. Here we show the development of ubiquitin (Ub)-based protein ligand multimers, referred to as U-bodies, which act as surrogate agonists for MET and are derived from MET-binding macrocyclic peptides. Monomeric Ub constructs (U-body) were first generated by genetic implantation of a macrocyclic peptide pharmacophore into a structural loop of Ub (lasso-grafting) and subsequent optimization of its flanking spacer sequences via mRNA display. Such U-body constructs exhibit potent binding affinity to MET, thermal stability, and proteolytic stability. The U-body constructs also partially/fully inhibited or enhanced HGF-induced MET-phosphorylation. Their multimerization to dimeric, tetrameric, and octameric U-bodies linked by an appropriate peptide linker yielded potent MET activation activity and downstream cell proliferation-promoting activity. This work suggests that lasso-grafting of macrocycles to Ub is an effective approach to devising protein-based artificial RTK agonists and it can be useful in the development of a new class of biologics for various therapeutic applications.

Keywords: Growth Factors; Peptides; Protein Engineering; Receptors; Signal Transduction.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Hepatocyte Growth Factor* / metabolism
  • Peptides / metabolism
  • Peptides / pharmacology
  • Phosphorylation
  • Protein Binding
  • Proto-Oncogene Proteins c-met / metabolism
  • Ubiquitin* / metabolism

Substances

  • Hepatocyte Growth Factor
  • Ubiquitin
  • Proto-Oncogene Proteins c-met
  • Peptides